BRTX Stock Overview
BioRestorative Therapies, Inc., a life sciences company, focuses on the development of regenerative medicine products and therapies using cell and tissue protocols primarily involving adult stem cells.
Snowflake Score | |
---|---|
Valuation | 2/6 |
Future Growth | 2/6 |
Past Performance | 0/6 |
Financial Health | 6/6 |
Dividends | 0/6 |
BioRestorative Therapies, Inc. Competitors
Price History & Performance
Historical stock prices | |
---|---|
Current Share Price | US$1.38 |
52 Week High | US$7.13 |
52 Week Low | US$1.20 |
Beta | 61.22 |
1 Month Change | 7.81% |
3 Month Change | -20.69% |
1 Year Change | -61.24% |
3 Year Change | -97.16% |
5 Year Change | -99.96% |
Change since IPO | -100.00% |
Recent News & Updates
Shareholder Returns
BRTX | US Biotechs | US Market | |
---|---|---|---|
7D | 3.8% | 0.9% | 0.2% |
1Y | -61.2% | 11.0% | 28.1% |
Return vs Industry: BRTX underperformed the US Biotechs industry which returned 10.3% over the past year.
Return vs Market: BRTX underperformed the US Market which returned 28.8% over the past year.
Price Volatility
BRTX volatility | |
---|---|
BRTX Average Weekly Movement | 22.9% |
Biotechs Industry Average Movement | 11.7% |
Market Average Movement | 6.1% |
10% most volatile stocks in US Market | 16.8% |
10% least volatile stocks in US Market | 3.0% |
Stable Share Price: BRTX's share price has been volatile over the past 3 months.
Volatility Over Time: BRTX's weekly volatility has increased from 16% to 23% over the past year.
About the Company
Founded | Employees | CEO | Website |
---|---|---|---|
1997 | 10 | Lance Alstodt | https://www.biorestorative.com |
BioRestorative Therapies, Inc., a life sciences company, focuses on the development of regenerative medicine products and therapies using cell and tissue protocols primarily involving adult stem cells. The company’s two core developmental programs relate to the treatment of disc/spine disease and metabolic disorders. Its disc/spine program (brtxDisc) includes a lead cell therapy candidate, BRTX-100, a product candidate formulated from autologous cultured mesenchymal stem cells collected from the patient’s bone marrow, which has completed Phase 1 clinical trials for use in the non-surgical treatment of painful lumbosacral disc disorders.
BioRestorative Therapies, Inc. Fundamentals Summary
BRTX fundamental statistics | |
---|---|
Market cap | US$9.13m |
Earnings (TTM) | -US$15.94m |
Revenue (TTM) | US$130.20k |
69.5x
P/S Ratio-0.6x
P/E RatioIs BRTX overvalued?
See Fair Value and valuation analysisEarnings & Revenue
BRTX income statement (TTM) | |
---|---|
Revenue | US$130.20k |
Cost of Revenue | US$0 |
Gross Profit | US$130.20k |
Other Expenses | US$16.07m |
Earnings | -US$15.94m |
Last Reported Earnings
Sep 30, 2023
Next Earnings Date
n/a
Earnings per share (EPS) | -2.43 |
Gross Margin | 100.00% |
Net Profit Margin | -12,241.03% |
Debt/Equity Ratio | 0% |
How did BRTX perform over the long term?
See historical performance and comparison